BRIVANEXT 25
Brivaracetam 25 mg
What it does
Brivaracetam is a medication used to help control seizures in people with epilepsy.
Commonly used for: seizures (epilepsy)
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Zambia Medicines Regulatory Authority · fetched 2026-04-24 14:12:15 · updated 2026-09-17 03:37:24
Drug Interactions
3Moderate (1)
Brivaracetam - decreases exposure
Rifampicin slightly decreases the exposure to antiepileptics (brivaracetam). Adjust dose.
Unknown (2)
Brivaracetam - decreases exposure
Enzalutamide is predicted to slightly decrease the exposure to antiepileptics (brivaracetam).
Brivaracetam - decreases exposure
StJohn’swortispredictedtodecreasetheexposureto brivaracetam.oTheoretical
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact
About this medicine
Brivaracetam is a medication used to help control seizures in people with epilepsy.
What it treats
- seizures (epilepsy)
How it works
Brivaracetam works by affecting certain chemicals in the brain to help reduce the frequency of seizures.
Who it's for
It is for people diagnosed with epilepsy who experience seizures.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Brivaracetam
BNF-referencedBrivaracetam is an antiepileptic medication used as adjunctive therapy for the treatment of focal seizures with or without secondary generalization in patients with refractory epilepsy. It is typically prescribed by experienced physicians.
Indications
- Focal seizures with or without secondary generalization
- Refractory epilepsy
Dosage
Children: For children aged 4-17 years with body weight 50 kg and above: initially 25-50 mg twice daily, adjusted according to response; usual maintenance 50 mg twice daily (max. per dose 100 mg twice daily). For children under 50 kg: initially 0.5-1 mg/kg twice daily, adjusted according to response; usual maintenance 1 mg/kg twice daily (max. per dose 2 mg/kg twice daily).
Adults: Initially, 50 mg twice daily, adjusted according to response; usual maintenance 100 mg twice daily (max. per dose 200 mg twice daily).
Mechanism of action
Brivaracetam binds to the synaptic vesicle protein 2A (SV2A), which is thought to modulate neurotransmitter release and inhibit excessive neuronal firing, thereby reducing seizure activity.
Pharmacodynamics
Brivaracetam exhibits anticonvulsant properties through its action on SV2A, leading to a decrease in the frequency of seizures. Its efficacy has been established in clinical trials for patients with focal seizures.
Pharmacokinetics
Brivaracetam is rapidly absorbed, with peak plasma concentrations typically occurring within 1 to 2 hours after oral administration. It has a high bioavailability, and its elimination half-life is approximately 8 to 9 hours. The drug is primarily metabolized by hydrolysis and does not significantly interact with cytochrome P450 enzymes.
Adverse effects
- Anxiety
- Decreased appetite
- Constipation
- Cough
- Depression
- Dizziness
- Drowsiness
- Irritability
Interactions
- Rifampicin: Moderate (decreases exposure)
- Enzalutamide: Unknown (decreases exposure)
- St. John's Wort: Unknown (decreases exposure)
Precautions
- Caution in hepatic impairment (risk of increased exposure)
- Avoid abrupt withdrawal-reduce daily dose gradually
Pregnancy
Manufacturer advises to avoid unless potential benefit outweighs risk-limited information available.
Breast-feeding
Manufacturer advises to avoid-present in milk in animal studies.
Storage
Store at room temperature. Protect from light.
Formulations
- Brivaracetam 10 mg per 1 ml oral solution
- Brivaracetam 25 mg tablets
- Brivaracetam 50 mg tablets
- Brivaracetam 75 mg tablets
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: Brivaracetam
PubChem CID 9837243Molecular formula: C11H20N2O2
Mechanism of action
The precise mechanism of brivaracetam's anti-epileptogenic activity is unknown.
Pharmacodynamics
Brivaracetam binds SV2A with high affinity. SV2A is known to play a role in epileptogenesis through modulation of synaptic GABA release. It is thought that brivaracetam exerts its anti-epileptogenic effects through its binding to SV2A. Brivaracetam is also known to inhibit Na+ channels which may also contribute to its anti-epileptogenic action.
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.